Stempeutics inaugurates second stem cell lab
This article was originally published in Scrip
Executive Summary
Stempeutics Research, part of India's Manipal Education and Medical Group, has inaugurated its second stem cell research and therapeutics lab at the Manipal University campus. The facility will be used for advanced stem cell research in human embryonic stem cells in collaboration with Manipal Assisted Reproduction Center. Stempeutics expects to conduct pilot studies to address the needs of patients with dilated cardiomyopathy, end stage liver disease and osteoarthritis. It also expects to establish large scale production of mesenchymal stem cells for clinical trials using an innovative upscaling process. Stempeutics, which aims to develop allogenic stem cell therapy in the future, currently focuses on bone marrow derived adult mesenchymal stem cells. The company's initial emphasis is on autologous cell therapies – where the bone marrow is aspirated from the patient, stem cells are isolated and upscaled and then injected back to the patient. Stempeutics is also setting up its third lab at Kuala Lumpur, which it expects to be operational in August.